HUTCHMED China Ltd (HCM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, HUTCHMED China Ltd (HCM) has a cash flow conversion efficiency ratio of -0.029x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-36.45 Million ≈ $-4.43K USD) by net assets (GBX1.24 Billion ≈ $151.11K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See HCM net asset quality index to measure how much of total assets are equity-financed.
HUTCHMED China Ltd - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how HUTCHMED China Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check HCM cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
HUTCHMED China Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HUTCHMED China Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Greenwing Resources Ltd
AU:GW1
|
0.008x |
|
Job Solution Sweden Holding AB
ST:JOBS
|
-0.019x |
|
New Zealand Energy Corp
V:NZ
|
-0.372x |
|
Astral Asia Bhd
KLSE:7054
|
0.003x |
|
Trilogiq
PA:ALTRI
|
0.004x |
|
Pungkang Co. Ltd
KQ:093380
|
0.048x |
|
Keyware Technologies NV
BR:KEYW
|
0.016x |
|
Polylite Taiwan Co Ltd
TWO:1813
|
0.109x |
Annual Cash Flow Conversion Efficiency for HUTCHMED China Ltd (2005–2025)
The table below shows the annual cash flow conversion efficiency of HUTCHMED China Ltd from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see HCM market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | GBX1.25 Billion ≈ $152.03K |
GBX-64.67 Million ≈ $-7.87K |
-0.052x | -8137.94% |
| 2024-12-31 | GBX771.85 Million ≈ $93.91K |
GBX497.00K ≈ $60.47 |
0.001x | -99.78% |
| 2023-12-31 | GBX743.39 Million ≈ $90.45K |
GBX219.26 Million ≈ $26.68K |
0.295x | +169.93% |
| 2022-12-31 | GBX636.87 Million ≈ $77.49K |
GBX-268.60 Million ≈ $-32.68K |
-0.422x | -114.67% |
| 2021-12-31 | GBX1.04 Billion ≈ $126.48K |
GBX-204.22 Million ≈ $-24.85K |
-0.196x | -64.27% |
| 2020-12-31 | GBX518.95 Million ≈ $63.14K |
GBX-62.07 Million ≈ $-7.55K |
-0.120x | +53.75% |
| 2019-12-31 | GBX312.90 Million ≈ $38.07K |
GBX-80.91 Million ≈ $-9.84K |
-0.259x | -224.54% |
| 2018-12-31 | GBX412.25 Million ≈ $50.16K |
GBX-32.85 Million ≈ $-4.00K |
-0.080x | -332.07% |
| 2017-12-31 | GBX484.97 Million ≈ $59.01K |
GBX-8.94 Million ≈ $-1.09K |
-0.018x | +60.68% |
| 2016-12-31 | GBX204.06 Million ≈ $24.83K |
GBX-9.57 Million ≈ $-1.16K |
-0.047x | +48.90% |
| 2015-12-31 | GBX102.28 Million ≈ $12.44K |
GBX-9.38 Million ≈ $-1.14K |
-0.092x | -182.34% |
| 2014-12-31 | GBX119.88 Million ≈ $14.59K |
GBX13.36 Million ≈ $1.63K |
0.111x | +132.36% |
| 2013-12-31 | GBX104.84 Million ≈ $12.76K |
GBX5.03 Million ≈ $611.76 |
0.048x | -74.38% |
| 2012-12-31 | GBX83.65 Million ≈ $10.18K |
GBX15.66 Million ≈ $1.91K |
0.187x | +178.34% |
| 2011-12-31 | GBX77.33 Million ≈ $9.41K |
GBX5.20 Million ≈ $632.88 |
0.067x | +123.36% |
| 2010-12-31 | GBX68.81 Million ≈ $8.37K |
GBX-19.82 Million ≈ $-2.41K |
-0.288x | -286.53% |
| 2009-12-31 | GBX75.30 Million ≈ $9.16K |
GBX11.63 Million ≈ $1.41K |
0.154x | +191.37% |
| 2008-12-31 | GBX84.43 Million ≈ $10.27K |
GBX-14.27 Million ≈ $-1.74K |
-0.169x | -91.86% |
| 2007-12-31 | GBX97.61 Million ≈ $11.88K |
GBX-8.60 Million ≈ $-1.05K |
-0.088x | -166.27% |
| 2006-12-31 | GBX109.98 Million ≈ $13.38K |
GBX-3.64 Million ≈ $-442.64 |
-0.033x | -106.81% |
| 2005-12-31 | GBX-28.01 Million ≈ $-3.41K |
GBX-13.60 Million ≈ $-1.65K |
0.485x | -- |
About HUTCHMED China Ltd
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast c… Read more